Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis.

Hammond SP, Martin ST, Roberts K, Gabardi S, Fuhlbrigge AL, Camp PC, Goldberg HJ, Marty FM, Baden LR.

Transpl Infect Dis. 2013 Apr;15(2):163-70. doi: 10.1111/tid.12036. Epub 2012 Dec 12.

PMID:
23230972
2.

Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.

Valentine VG, Weill D, Gupta MR, Raper B, Laplace SG, Lombard GA, Bonvillain RW, Taylor DE, Dhillon GS.

J Heart Lung Transplant. 2008 Aug;27(8):875-81. doi: 10.1016/j.healun.2008.05.009. Epub 2008 Jun 30.

PMID:
18656801
3.

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.

Transplantation. 1998 Dec 27;66(12):1682-8.

PMID:
9884259
4.

Cytomegalovirus infection in lung transplant patients: the role of prophylaxis and recipient-donor serotype matching.

Burton CM, Kristensen P, Lützhøft R, Rasmussen M, Milman N, Carlsen J, Christiansen CB, Andersen CB, Iversen M.

Scand J Infect Dis. 2006;38(4):281-9.

PMID:
16715596
5.

Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.

Kruger RM, Paranjothi S, Storch GA, Lynch JP, Trulock EP.

J Heart Lung Transplant. 2003 Jul;22(7):754-63.

PMID:
12873543
6.

Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.

Ruttmann E, Geltner C, Bucher B, Ulmer H, Höfer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Müller LC.

Transplantation. 2006 May 27;81(10):1415-20.

PMID:
16732179
7.

Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.

Lopez Garcia-Gallo C, García Fadul C, Laporta R, Portero F, Millan I, Ussetti P.

Ann Transplant. 2015 Nov 5;20:661-6.

8.

Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.

Fallatah SM, Marquez MA, Bazerbachi F, Schiff JR, Cattral MS, McGilvray ID, Norgate A, Selzner M, Rotstein C, Husain S.

Clin Transplant. 2013 Jul-Aug;27(4):503-9. doi: 10.1111/ctr.12138. Epub 2013 Jun 3.

PMID:
23731387
9.

Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.

Kaufman DB, Leventhal JR, Gallon LG, Parker MA, Koffron AJ, Fryer JP, Abecassis MM, Stuart FP.

Transplantation. 2001 Dec 27;72(12):1940-5.

PMID:
11773893
10.

Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.

Beam E, Lesnick T, Kremers W, Kennedy CC, Razonable RR.

Clin Transplant. 2016 Mar;30(3):270-8. doi: 10.1111/ctr.12686. Epub 2016 Mar 1.

PMID:
26701733
11.

Epidemiology of cytomegalovirus infection after pancreas transplantation.

Parsaik AK, Bhalla T, Dong M, Rostambeigi N, Dierkhising RA, Dean P, Abraham R, Prieto M, Kremers WK, Razonable RR, Kudva YC.

Transplantation. 2011 Nov 15;92(9):1044-50. doi: 10.1097/TP.0b013e31823015c1.

PMID:
21904269
12.

Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.

Bonaros NE, Kocher A, Dunkler D, Grimm M, Zuckermann A, Ankersmit J, Ehrlich M, Wolner E, Laufer G.

Transplantation. 2004 Mar 27;77(6):890-7.

PMID:
15077033
13.

Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients.

Kocher AA, Bonaros N, Dunkler D, Ehrlich M, Schlechta B, Zweytick B, Grimm M, Zuckermann A, Wolner E, Laufer G.

J Heart Lung Transplant. 2003 Mar;22(3):250-7.

PMID:
12633691
14.

Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.

Gutiérrez CA, Chaparro C, Krajden M, Winton T, Kesten S.

Chest. 1998 Apr;113(4):924-32.

PMID:
9554627
15.

Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?

Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV.

Liver Transpl. 2005 Jun;11(6):700-4.

16.

Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.

Murray BM, Subramaniam S.

Transpl Infect Dis. 2004 Mar;6(1):3-9.

PMID:
15225220
17.

Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.

Palmer SM, Grinnan DC, Diane Reams B, Steele MP, Messier RH, Duane Davis R.

Clin Transplant. 2004 Apr;18(2):179-85.

PMID:
15016133
18.
19.

Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant, 1997-1999.

Smits JM, Vanhaecke J, Haverich A, de Vries E, Smith M, Rutgrink E, Ramsoebhag A, Hop A, Persijn G, Laufer G.

Clin Transpl. 2003:89-100.

PMID:
15387100
20.

Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients.

Wreghitt TG, Abel SJ, McNeil K, Parameshwar J, Stewart S, Cary N, Sharples L, Large S, Wallwork J.

Transpl Int. 1999;12(4):254-60.

Supplemental Content

Support Center